| Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. | |
| | |
MedLine Citation:
|
PMID: 20482616 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To investigate whether specific markers for innate immunity would diminish with successful treatment in psoriasis, we analyzed lesional and non-lesional skin biopsies taken from patients with moderate to severe psoriasis during 12 weeks of treatment with etanercept in correlation with the clinical response. In the clinical responders (PASI reduction >50%), all markers (CD3, CD68, CD161, elastase, BDCA-2, TNF-alpha) showed a decline during treatment, indicating a pivotal role for innate immunity in the pathogenesis of psoriasis. |
| | |
Authors:
|
Marjan de Groot; Marcel B M Teunissen; Daisy I Picavet; Menno A de Rie; Jan D Bos |
Related Documents
:
|
18923446 - The human antimicrobial peptide ll-37 suppresses apoptosis in keratinocytes. 10671976 - Bacterial superantigens and inflammatory skin diseases. 19264456 - Increased expression of il-12p70 and il-23 by multiple dendritic cell and macrophage su... 429796 - Inhibition of lymphocyte cytotoxicity and mitogen-induced transformation of lymphocytes... 19700686 - The effect of floor surface on dairy cow immune function and locomotion score. 9476656 - Is hematopoiesis under the influence of neural and neuroendocrine mechanisms? |
Publication Detail:
|
Type: Letter |
Journal Detail:
|
Title: Experimental dermatology Volume: 19 ISSN: 1600-0625 ISO Abbreviation: Exp. Dermatol. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-26 Completed Date: 2011-01-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9301549 Medline TA: Exp Dermatol Country: Denmark |
Other Details:
|
Languages: eng Pagination: 754-6 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-Inflammatory Agents, Non-Steroidal / therapeutic use* Antigens, CD / metabolism Antigens, CD3 / metabolism Antigens, Differentiation, Myelomonocytic / metabolism Biological Markers / metabolism Biopsy Female Humans Immunity, Innate* Immunoglobulin G / therapeutic use* Lectins, C-Type / metabolism Male Membrane Glycoproteins / metabolism Middle Aged NK Cell Lectin-Like Receptor Subfamily B / metabolism Pancreatic Elastase / metabolism Psoriasis / drug therapy*, metabolism, pathology* Receptors, Immunologic / metabolism Receptors, Tumor Necrosis Factor / therapeutic use* Skin / metabolism, pathology* Tumor Necrosis Factor-alpha / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antigens, CD; 0/Antigens, CD3; 0/Antigens, Differentiation, Myelomonocytic; 0/Biological Markers; 0/CD68 antigen, human; 0/CLEC4C protein, human; 0/Immunoglobulin G; 0/Lectins, C-Type; 0/Membrane Glycoproteins; 0/NK Cell Lectin-Like Receptor Subfamily B; 0/Receptors, Immunologic; 0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factor-alpha; 185243-69-0/TNFR-Fc fusion protein; EC 3.4.21.36/Pancreatic Elastase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Zeaxanthin inhibits PDGF-BB-induced migration in human dermal fibroblasts.
Next Document: Antioxidative characteristics and inhibition of alpha-melanocyte-stimulating hormone-stimulated mela...